Cargando…
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Autores principales: | Bolaños-Mateo, Elixabet, Weigelin, Bettina, Teijeira, Alvaro, Martinez-Forero, Ivan, Labiano, Sara, Azpilicueta, Arantza, Morales-Kastresana, Aizea, Quetglas, Jose I, Wagena, Esther, Rodriguez, Alfonso, Chen, Lieping, Friedl, Peter, Melero, Ignacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288781/ http://dx.doi.org/10.1186/2051-1426-2-S3-P95 |
Ejemplares similares
-
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
por: Morales-Kastresana, Aizea, et al.
Publicado: (2013) -
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014) -
Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma
por: Morales-Kastresana, Aizea, et al.
Publicado: (2013) -
Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer
por: Morales-Kastresana, Aizea, et al.
Publicado: (2014) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)